clinical trials

Lantern Pharma Subsidiary Starlight Therapeutics Names New Chief Medical Officer to Oversee Clinical Trials

by | Jan 19, 2024

Marc Chamberlain, M.D., has been appointed as the Chief Medical Officer at Starlight Therapeutics.

Starlight Therapeutics is a Dallas-based Lantern Pharma subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options.

In his role as CMO, Chamberlain will oversee the company’s upcoming clinical trials focused on several serious and complex brain-related conditions: glioblastoma and other high-grade gliomas (aggressive types of brain tumor), brain metastases in adults (secondary brain tumors originating from cancer elsewhere in the body), and two types of pediatric brain tumors — atypical teratoid rhabdoid tumors (ATRT) and diffuse intrinsic pontine glioma (DIPG)....

MORE
Federal Health Agency Plugs Into Texas With Ambitious Clinical Trials Push
The Advanced Research Projects Agency for Health—or ARPA-H— wants to enable 90% of eligible Americans to participate in clinical trials within 30 minutes of their homes. The agency officially launched its new Texas "customer experience" headquarters at Dallas' Pegasus Park on Thursday, which will be home base for the initiative.
MORE
The Last Word: Nicole Small On Why the Dallas-Based ARPA-H Hub Is Focused on Clinical Trials
by | Oct 20, 2023
The Dallas-based customer experience hub of the Advanced Research Projects Agency for Health had its official launch yesterday at Pegasus Park. The hub's first mission: making it easier for Americans from across the country to take part in clinical trials, through the Advancing Clinical Trial Readiness Initiative.
MORE
Nanoscope Therapeutics Strengthens Clinical, Regulatory Expertise with Appointment of Chief Medical Officer
by | Sep 22, 2023
Samuel Barone, M.D., is a former Federal Drug Administration official and leader in the pharmaceutical space.
MORE

Public-Private Consortium Will Fund 3 Gene Therapy Clinical Trials at UT Southwestern

by | Jun 22, 2023
"There are over 10,000 rare diseases that affect millions of people worldwide, and most of them are genetic," notes UT Southwestern's Steven Gray (above, with Susan Iannaccone, M.D.). Testing on a total of eight genetic diseases has been approved for funding by the Bespoke Gene Therapy Consortium and other organizations.
MORE
Nanoscope Therapeutics Bolsters Board with Addition of Ophthalmic Veteran as Strategic Adviser
by | Mar 22, 2023
Nanoscope Therapeutics has enlisted the expertise of Vicente Anido Jr., Ph.D. to help the company advance its goal of developing sight-restoring gene therapies for retinal degenerative diseases. Anido's appointment as a strategic adviser is expected to support Nanoscope's clinical and corporate strategies, especially as the company progresses towards the potential commercialization of MCO-010.
MORE
5 Ways UT Southwestern Medical Center Is Fighting COVID
by | Aug 4, 2020
Virus researchers at UT Southwestern Medical Center have amped up their lab and data work to fight and defeat COVID-19. Here are key takeaways from UTSW's Claire Aldridge, who herself has battled the virus and fully recovered.
MORE

Caris Life Sciences Acquires Pharmatech to Pair Patients with Clinical Trials, Faster

by | May 2, 2019
Using a patient's molecular makeup, Caris and Pharmatech aim to find the perfect clinical trial for each cancer patient—and enroll them in as little as 10 days.
MORE
eye
R&D: UNTHSC Finds Hope for Sight-Stealing Eye Disease, UTA Engineers Stronger Walls with Recycled Plastic
by | Oct 12, 2018
Also, you'll learn how Galderma has boosted its R&D investment and boosted its clinical trials. Here are some of the research projects underway in North Texas that could make lives better.
MORE
thinking
Discovery: Innovative Thinking Study, Cancer Survivors & Clinical Trials, Quake Sensors
by | Dec 1, 2017
Researchers are making discoveries and breakthroughs at laboratories and institutions all across North Texas. Here are some of their stories.
MORE